Advances in the Management of **Prostate, Kidney, and Bladder Cancers**



September 29 to 30, 2023 Washington Marriott Georgetown • Washington, D.C.

Course Directors:

MICHAEL B. ATKINS, MD

Georgetown University Medical Center MedStar Georgetown University Hospital MedStar Georgetown Cancer Institute Washington, D.C.

MOHIT GUPTA, MD

MedStar Georgetown University Hospital Georgetown University School of Medicine Washington, D.C.

KEITH J. KOWALCZYK, MD

MedStar Georgetown University Hospital Georgetown University School of Medicine Washington, D.C.

ROSS E. KRASNOW, MD, MPH

MedStar Washington Hospital Center Washington, D.C.

YOUNG KWOK, MD

Maryland Proton Treatment Center University of Maryland Medical Center University of Maryland School of Medicine Baltimore, MD

PAUL D. LEGER, MD, MPH

MedStar Georgetown University Hospital Washington, D.C.

GEORGE K. PHILIPS, MBBS, MD, MPH

MedStar Washington Hospital Center Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Georgetown University School of Medicine Washington, D.C.

SUTHEE RAPISUWON, MD

MedStar Georgetown University Hospital Georgetown University School of Medicine Washington, D.C.



Course Description

MedStar Health is proud to bring you this blended conference with the most up-to-date comprehensive care and education for the kidney, bladder, and prostate. During this conference, you can attend high-caliber lectures along with questions and discussion time focusing on these three cancer areas. Expert faculty will deliver state-of-the-art lectures that will include treatment approaches, clinical trials, biologic and genomic factors, and future directions. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them.

Advances in Prostate Cancer reviews recent advances in the diagnosis and treatment of patients with localized and advanced prostate cancer. Key clinical topics will include the use of biomarkers and modern imaging technologies in the management of early-stage prostate cancer as well as advances in the multidisciplinary approach to patients with high-risk, locally advanced, relapsed non-metastatic, and metastatic prostate cancer. Applications of new therapeutic agents, cutting-edge radiation technology, combined modality strategies, and evolving minimally invasive urologic surgical approaches will also be discussed.

Advances in Kidney Cancer will review the approaches to the treatment of patients with small renal masses and the role of cytoreductive nephrectomy and an update on adjuvant therapy. Expert speakers will also present the latest front-line and subsequent systemic therapy approaches as well as the treatment of patients with non-clear cell RCC.

Advances in Bladder Cancer is a comprehensive session that explores the latest advances in bladder cancer diagnosis, management, and treatment. With a focus on innovative approaches and emerging therapies, participants will gain valuable insights into various aspects of bladder cancer care. During the lectures, it will cover a range of topics, including BCG unresponsive non-muscle invasive bladder cancer, management strategies for muscle-invasive bladder cancer, and cutting-edge developments in bladder cancer surgery. Additionally, the talks delve into clinical trials, upper tract urothelial carcinoma, and advances in systemic therapy for metastatic urothelial carcinoma, ensuring a well-rounded understanding of the current bladder cancer landscape.

Learning Objectives

- Describe emerging treatments, endpoints, and predictive biomarkers for RCC management.
- Describe the role of immunotherapy and novel targeted therapies for upper tract and chemotherapy-refractory carcinoma.
- Describe symptom management, supportive care, procedural, and pharmacological basis of treating prostate and bladder cancers.
- Discuss the current treatment algorithm for patients with metastatic clear cell and non-clear cell RCC.
- Describe the evolving role of surgery in the management of patients with all stages of kidney cancer.
- Discuss the evolving roles of urology and medical oncology in the management of localized bladder cancer.
- Discuss the recent advances in multi-modality evaluation and management of early stage of prostate cancer.
- Discuss the biology and evolving therapeutics for advanced prostate cancer.
- Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with prostate, kidney, and bladder cancers.
- Integrate a team-based approach in the care of patients with prostate, kidney, and bladder cancer.

Continuing Education Credit Information

Target Audience

This conference is intended for physicians, residents and fellows, physician assistants, nurse practitioners, nurses, allied health professionals, medical oncologists, oncologists, pathologists, radiation oncologists, radiologists, surgeons, urologists, and other members of the healthcare team interested in the management of prostate, kidney, and bladder cancers.

Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation



This activity was planned by and for the healthcare team, and learners will receive 10.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



American Board of Internal Medicine MOC Credit: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It

is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



American Board of Surgery CC Credit: Successful completion of this CME THE AMERICAN BOARD OF SURGERY activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of

the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC/CC Participation Threshold: Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 10.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Course Directors



Michael B. Atkins, MD

Deputy Director, Georgetown Lombardi Comprehensive Cancer Center William M. Scholl Professor and Vice-Chair Department of Oncology Georgetown University Medical Center Staff Physician, Hematology/Oncology MedStar Georgetown University Hospital Washington, D.C.



Mohit Gupta, MD

Director, Urologic Oncology Urologic Oncologist MedStar Georgetown University Hospital Associate Professor, Urology Georgetown University School of Medicine Washington, D.C.



Keith J. Kowalczyk, MD Physician Executive Director MedStar Health Urology Chair, Department of Urology Chair, MedStar Robotic Surgery Service Line MedStar Georgetown University Hospital Georgetown University Medical Center Washington, D.C.



Ross E. Krasnow, MD, MPH Staff Physician, Urologic Oncologist MedStar Washington Hospital Center

Washington, D.C.



Young Kwok, MD Professor, Radiation Oncology Maryland Proton Treatment Center University of Maryland Medical Center University of Maryland School of Medicine Baltimore, MD



Paul D. Leger, MD, MPH Medical Oncologist MedStar Georgetown University Hospital Washington, D.C.



George K. Philips, MBBS, MD, MPH Vice Chair, Medicine

Vice Chair, Medicine Staff Physician, Hematology/Oncology MedStar Georgetown University Hospital Georgetown Lombardi Comprehensive Cancer Center Washington, D.C.



Suthee Rapisuwon, MD Attending Physician, Hematology-Oncology MedStar Georgetown University Hospital Assistant Professor, Oncology Georgetown University School of Medicine Washington, D.C.

Faculty

Gerald L. Andriole, MD

Chief, Medical Officer Prostatype Genomics St Louis, MO

Andrea B. Apolo, MD

Head, Bladder Cancer Section Director, Bladder Cancer and Genitourinary Tumors National Cancer Institute National Institutes of Health Bethesda, MD

Sean P. Collins, MD, PhD

Director, CyberKnife Prostate Program MedStar Georgetown University Hospital Professor, Radiation Medicine Georgetown University School of Medicine Washington, D.C.

Samuel Ray Denmeade, MD

Director, Genitourinary Oncology Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Professor, Oncology and Urology Johns Hopkins University School of Medicine Baltimore, MD

Giuseppe Esposito, MD

Chief, Nuclear Medicine and PET/CT MedStar Georgetown University Hospital Professor, Radiology Georgetown University Medical Center Washington, D.C.

Kirsten L. Greene, MD

Paul Mellon Professor and Chair Department of Urology University of Virginia Charlottesville, VA

Hans Hammers, MD, PhD

Professor, Internal Medicine The University of Texas Southwestern Medical Center Dallas, TX

Ryan A. Hankins, MD

Urologic Surgeon MedStar Georgetown University Hospital Assistant Professor, Urology Georgetown University School of Medicine Washington, D.C.

Max Kates, MD

Director, Bladder Cancer Program Division Director, Urologic Oncology Associate Professor, Urology and Oncology Johns Hopkins University Baltimore, MD

David F. McDermott, MD

Chief, Medical Oncology Beth Israel Deaconess Medical Center Leader, Kidney Cancer Program Dana-Farber/Harvard Cancer Center Professor, Medicine Harvard Medical School Boston, MA

Krishnan R. Patel, MD

Radiation Oncologist National Cancer Institute National Institutes of Health Bethesda, MD

Peter A. Pinto, MD

Head, Prostate Cancer Section Director, Fellowship Program Urologic Oncology Branch National Cancer Institute National Institutes of Health Bethesda, MD

Brian I. Rini, MD

Chief, Clinical Trials Vanderbilt-Ingram Cancer Center Professor, Medicine Division of Hematology/Oncology Vanderbilt University Medical Center Nashville, TN

Michael Serzan, MD

Medical Oncologist, Genitourinary Oncology Dana-Farber Cancer Institute Instructor, Medicine Harvard Medical School Boston, MA

Nathan M. Shaw, MD

Trauma and Reconstructive Urologist MedStar Georgetown University Hospital MedStar Washington Hospital Center Assistant Professor, Urology Georgetown University School of Medicine Washington, D.C.

Nicholas I. Simon, MD, MSc

Assistant Research Physician National Cancer Institute National Institutes of Health Bethesda, MD

Gajan Sivananthan, MD

Attending Physician, Vascular & Interventional Radiology MedStar Washington Hospital Center Associate Program Director, Vascular & Interventional Radiology Residency Assistant Professor, Radiology Georgetown University School of Medicine Washington, D.C.

Lambros Stamatakis, MD

Director, Urologic Oncology MedStar Washington Hospital Center Associate Professor, Urology Georgetown University School of Medicine Washington, D.C.

Samir Taneja, MD

Director, Urologic Oncology Professor, Urology and Radiology NYU Langone Medical Center New York, NY


Ryan Werntz, MD

Instructor, Surgery University South Carolina School of Medicine Greenville Greenville, SC

Agenda | Friday, September 29

12:00 p.m.	Lunch, Registration and Visit the Exhibitors	3:20 p.m.	Stereotactic Body Radiation Therapy for Prostate Cancer: An Alternative to Conventionally Fractionated Radiation Therapy?
	II PROSTATE CANCER		Sean P. Collins, MD, PhD
12:45 p.m.	Welcome Remarks and Introduction Keith J. Kowalczyk, MD	3:40 p.m.	Prostate-Specific Membrane Antigen (PSMA)/Theranostics Giuseppe Esposito, MD
12:50 p.m.	MicroUltrasound of the Prostate Gerald L. Andriole, MD	4:00 p.m.	KEYNOTE: Navigating the Increasingly Complicated
1:10 p.m.	Optimizing Prostate Biopsy/MRI vs High-Frequency Ultrasound in the Detection of Prostate Cancer Samir Taneja, MD		Landscape of Hormone Therapy for Prostate Cancer Samuel Ray Denmeade, MD
1:30 p.m.	Active Surveillance High Genetic Risk Patients Peter A. Pinto, MD	4:30 p.m.	Prostate Cancer Panel Discussion II Moderator: Mohit Gupta, MD Panelists: S. Denmeade, S. Collins, G. Esposito, K. Greene, N. Shaw,
1:50 p.m.	Prostate Cancer Panel Discussion I Moderator: Mohit Gupta, MD Panelists: P. Pinto, S. Taneja	4:45 p.m.	Y. Kwok Adjourn
2:05 p.m.	Break and Visit Exhibits	4:50 p.m.	Networking Reception with
2:20 p.m.	Pelvic Fascial Sparing Robotic Radical Prostatectomy: The Evolution of Continence Kirsten L. Greene, MD		Exhibitors Food, Drinks, & Networking Opportunities You Won't Want to Miss!
2:40 p.m.	Stress Urinary Incontinence in Prostate Cancer Survivors Nathan M. Shaw, MD		
3:00 p.m.	Prostate Cancer Update:		

Radiation Oncology Young Kwok, MD



For updated information, visit MedStarHealth.org/ProstateKidneyBladderCancers

Agenda | Saturday, September 30

7:30 a.m.	Breakfast, Registration, and Visit the Exhibits			
SESSION II KIDNEY CANCER Moderator: Michael B. Atkins, MD				
8:30 a.m.	To Treat or Not to Treat: The Adjuvant Therapy Morass Hans Hammers, MD, PhD			
8:50 a.m.	Surgical Management in Metastatic Renal Cell Carcinoma (RCC) Mohit Gupta, MD			
9:10 a.m.	First Line Therapy-IO/IO vs IO/TKI - Debate David F. McDermott, MD; Brian I. Rini, MD			
9:40 a.m.	The Treatment Choice Dilemma in Favorable Risk RCC Michael B. Atkins, MD			
9:50 a.m.	Subsequent Therapy Options and Sequencing in Advanced RCC Brian I. Rini, MD			
10:05 a.m.	Kidney Cancer Panel Discussion I Moderator: Michael B. Atkins, MD Panelists: M. Gupta, H. Hammers, D. McDermott, B. Rini			
10:20 a.m.	Morning Break and Visit the Exhibits			
10:35 a.m.	Update on Minimally Invasive Surgical Management of RCC Ross E. Krasnow, MD, MPH			
10:55 a.m.	Renal Cell Carcinoma Focal Therapy Gajan Sivananthan, MD			
11:15 a.m.	Renal Cell Carcinoma with Variant Histology Michael Serzan, MD			
11:35 a.m.	Biomarkers and Alternative Endpoints David F. McDermott, MD			
11:50 a.m.	Kidney Cancer Panel Discussion II Moderator: Michael B. Atkins, MD Panelists: R. Krasnow, D. McDermott, M. Serzan, G. Sivananthan			
12:05 p.m.	Lunch and Visit the Exhibits			

12:25 p.m

LUNCH SYMPOSIUM A Treatment for Relapsed/ Refractory RCC

Deepak Kilari, MD | Dupont Room

Sponsored by AVEO Oncology This symposium is not certified for continuing education credit.

1:10 p.m.

Visit the Exhibits, Dessert and Coffee Break

SESSION III | BLADDER CANCER

Moderator: Lambros Stamatakis, MD

1:25 p.m.	Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Lambros Stamatakis, MD
1:45 p.m.	Trimodality Therapy for Muscle Invasive Bladder Cancer (MIBC) Krishnan R. Patel, MD
2:05 p.m.	Cystectomy Related Complications and Management Ryan Werntz, MD
2:25 p.m.	Bladder Cancer Panel Discussion I Moderator: Lambros Stamatakis, MD Panelists: K. Patel, R. Werntz
2:40 p.m.	Afternoon Break and Visit the Exhibits
2:55 p.m.	KEYNOTE: Updates in NMIBC Trials Max Kates, MD
3:15 p.m.	Perioperative Management of Upper Tract Urothelial Carcinoma Nicholas I. Simon, MD, MSc
3:15 p.m. 3:35 p.m.	Upper Tract Urothelial Carcinoma
	Upper Tract Urothelial Carcinoma Nicholas I. Simon, MD, MSc Advances in Systemic Therapy for Advanced Urothelial Carcinoma
3:35 p.m.	Upper Tract Urothelial Carcinoma Nicholas I. Simon, MD, MSc Advances in Systemic Therapy for Advanced Urothelial Carcinoma Andrea B. Apolo, MD Robotic Intracorporeal Urinary Diversions 101
3:35 p.m. 3:50 p.m.	Upper Tract Urothelial Carcinoma Nicholas I. Simon, MD, MSc Advances in Systemic Therapy for Advanced Urothelial Carcinoma Andrea B. Apolo, MD Robotic Intracorporeal Urinary Diversions 101 Ryan A. Hankins, MD Bladder Cancer Panel Discussion II Moderator: Lambros Stamatakis, MD Panelists: A. Apolo, R. Hankins,

Registration Information

Registration Fees

Physician	\$150
Resident or Fellow	\$50
Physician Assistant	\$50
Nurse Practitioner	\$50
Nurse	\$50
Allied Health Professional	\$50
Medical Student	\$50
Industry Professional	\$200

Online Registration Preferred

Please visit **MedStarHealth.org/ProstateKidneyBladderCancers** for updated program and registration information. We are unable to accept registrations or cancellations by telephone. All registrations will be confirmed by email only. If you have questions or do not receive a confirmation within 1-2 business days, please contact us at MedStarCPE@MedStar.net or (833) 731-1273.

Cancellation Policy

Cancellations made in writing by August 15 will be subject to a 50% penalty. No refunds will be given after August 15. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee but is not responsible for any travel costs.



For grant information please contact Ada Guo at ada.guo@medstar.net For exhibit support information please contact Elizabeth Romano at elizabeth.s.romano@medstar.net